Why Special Blood Products?
-
Upload
fay-cantrell -
Category
Documents
-
view
35 -
download
1
description
Transcript of Why Special Blood Products?
![Page 1: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/1.jpg)
Salwa Hindawi
Salwa Hindawi MSc, FRCPath, CTM
Director of Blood Transfusion ServiceskAUH, Jeddah
Saudi Arabia
ESPHO Cairo 2008
![Page 2: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/2.jpg)
Salwa Hindawi
Despite general measures to ensure transfusion safety, there still an added risk to infants and children with underlying hematological, oncologic and immunologic disorders.
Transfusion reaction may be caused by both infectious or non infectious processes.
Special products are blood components collected, processed, and selected specifically to minimize these complications.
![Page 3: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/3.jpg)
Salwa Hindawi
CMV is transmitted by leucocytes.
The use of CMV-seronegative blood components has been shown to reduce the incidence of CMV infection to 1-3%.
![Page 4: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/4.jpg)
Salwa Hindawi
Patients with congenital immunodeficiency disorders AIDS (human immunodeficiency virus infection) patients Hematopoietic progenitor cell transplant recipients Organ allograft transplant recipients Premature infants during infancy Cancer patients undergoing intense chemotherapy Recipients of intrauterine transfusions
![Page 5: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/5.jpg)
Salwa Hindawi
Leucocytes in the blood components can lead to many complications
Universal Leucodepletion verses specific indications.
![Page 6: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/6.jpg)
Salwa Hindawi
Nonhemolytic transfusion reactions (commonly called “febrile nonhemolytic transfusion reactions”)
Alloimmunization to HLA Class I antigens
Cytomegalovirus infections
Immune modulation
Graft-vs-host disease
![Page 7: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/7.jpg)
Salwa Hindawi
WHY? To Prevent Graft verses Host Disease mediated by T
lymphocytes in units of Packed RBCs, Platelets, and Granulocytes.
Blood components that contain viable lymphocytes
may be irradiated to prevent proliferation of T lymphocytes, which is the immediate cause of GVHD.
The standard dose of gamma irradiation is 2500 cGy , maximum allowable dose is 5000cGy.
![Page 8: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/8.jpg)
Salwa Hindawi
Patients with congenital immunodeficiency disorders of cellular immunity.
Intrauterine transfusion and neonatal exchange transfusion recipients.
Hematopoietic progenitor cell transplant recipients.
Recipients of blood components from 1st & 2nd degree relatives.
![Page 9: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/9.jpg)
Salwa Hindawi
Patients receiving HLA-matched cellular blood components.
Patients with hematologic malignancies and Cancer patients
undergoing intense chemotherapy or Hodgkin’s disease receiving fludarabine.
![Page 10: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/10.jpg)
Salwa Hindawi
Sickle cell trait:
Hb A = 60%
Hb S = 40%
Hypoxia and acidosis can lead to sickle crisis.
Can donate blood.
![Page 11: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/11.jpg)
Salwa Hindawi
Define patients populations who should receive red blood cells known to lack hemoglobin S.
1- infants with small blood volume or massive transfusion in neonates.
2- Sickle cell patients
![Page 12: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/12.jpg)
Salwa Hindawi
The risk of:
Bacterial contamination
Emerging pathogens
are still a major concerns which lead to the need for better techniques.
PI for platelet concentrates have been in routine use since 2002 and for plasma in 2006 (INTERCEPT blood system).
A noval PI approach to blood safety (the Mirasol PRT System).
![Page 13: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/13.jpg)
Salwa Hindawi
Nucleic acid targeted pathogen inactivation technologies offer the potential to protect from infectious and non infectious processes through prevention of cell replication and transcription.
To accurately assess the true value of a pathogen reduction system it is essential to weigh its cost against the saving it offers in terms of quality of life and reduced cost to society.
![Page 14: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/14.jpg)
Salwa Hindawi
Reduction of viruses, bacteria, parasitesInactivation of residual white cells
MIRASOL PRT system for platelets
and plasma – Concept
+Riboflavin
(Vitamin B2)UV Light
Platelet or plasma product
+
![Page 15: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/15.jpg)
Salwa Hindawi
The MIRASOL PRT process:
Transfer platelet product to MIRASOL
Illumination bag
1 2
Add 35 mL Riboflavin Solution
(500 uM)
3
Illuminate product for
6-10 min*.
*Illumination time depends on product volume
![Page 16: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/16.jpg)
Salwa Hindawi
delayed clamping of the umbilical cord;
restricting blood sampling
using recombinant human erythropoietin to stimulate erythropoiesis
using iron supplementation or vitamins to minimize the severity of anemia
![Page 17: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/17.jpg)
Salwa Hindawi
using appropriately collected and stored multipack RBC units
using appropriately screened and handled RBCs from regular or designated donors; and
collecting and transfusing umbilical cord
blood (autologous blood transfusion).
![Page 18: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/18.jpg)
Salwa Hindawi
The use of special products is a must for specific patients in pediatric age group to ensure safety.
The use of PI procedures are recommended to ensure better safety.
Training for the staff, policies, and guidelines in pediatric age group are important issues to be considered.
![Page 19: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/19.jpg)
Salwa Hindawi
Pediatric Transfusion, A Physician’s handbook 2nd Edition, 2006. Prenatal and childhood transfusion, Practical
Transfusion Medicine 2001. A novel Approach to blood safety, Gambro BCT 2007. Impact of Pathogen activation on platelets utilization
during 3 years of routine use, AABB October 2007. Pathogen Inactivation making decisions about new
technologies preliminary reports of a consensus conference, Vox Sanguinis 2007.
![Page 20: Why Special Blood Products?](https://reader035.fdocuments.us/reader035/viewer/2022062308/56812c61550346895d90f2ff/html5/thumbnails/20.jpg)
Salwa Hindawi